Survey Confirms the CyberKnife(R) System as the Only

[dadstimeon]

Extracranial Radiosurgery Device in Widespread Use

http://www.prnewswire.com/cgi-bin/stori ... 533&EDATE=

SUNNYVALE, Calif., March 19 /PRNewswire-FirstCall/ -- Accuray

Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery,

announced today the results of an independent survey that confirms that the

CyberKnife® Robotic Radiosurgery System dominates the field of

extracranial radiosurgery. The survey concludes that hospitals with

combined radiotherapy and radiosurgery systems, also known as "all-purpose"

units, are rarely utilizing the extracranial radiosurgery capabilities. In

fact, the survey, which included more than 1,600 hospitals and radiation

oncology facilities, shows that for 88 percent of the all-purpose systems

in use today, less than 10 percent of the procedures were extracranial

radiosurgery.

The technique of radiosurgery was introduced more than 20 years ago for

the treatment of brain tumors. At this time, radiosurgical accuracy was

achieved using an invasive device, known as a stereotactic frame. This

frame was designed to hold the head still by screwing a metal frame into

the patient's skull. Use of this invasive frame limited radiosurgery to

intracranial treatments (treatments of tumors inside the head).

The CyberKnife System achieves the same accuracy as frame-based

radiosurgery, but uses image guided robotics to avoid the need for a frame.

This approach is not only less invasive for intracranial treatments but has

also made extracranial radiosurgery possible (treatment of tumors

throughout the body). This independent survey confirms that, while

manufacturers of other technologies may make claims about extracranial

radiosurgery capabilities for their equipment, the CyberKnife System

remains the only extracranial radiosurgery technology in widespread

clinical use.

According to the American Cancer Society's Cancer Facts & Figures 2007,

an estimated 1.4 million new cancer cases will be diagnosed this year in

the United States. Of these cases a large percentage are candidates for

radiosurgery, however the survey results indicate that healthcare

facilities are not capitalizing on the opportunity to provide extracranial

radiosurgical treatment to a large number of these patients, particularly

those who have been diagnosed with surgically complex or inoperable tumors.

Evidence shows that hospitals that have supplemented their radiotherapy

or all-purpose units with a dedicated robotic radiosurgery system, such as

the CyberKnife System, have nearly doubled the number of cancer patients

treated.

After installing a CyberKnife System in 2002, Georgetown University

Hospital in Washington, D.C., treated 95 patients with extracranial tumors

and 105 patients with intracranial tumors in the first year alone. Over the

past three years, the hospital reports that the treatment of both

extracranial and intracranial cases has increased 150 percent and 55

percent respectively, with many cases involving tumors in the spine and

lungs.

"Not only has the dedicated robotic radiosurgery system expanded our

ability to help our existing cancer patients, it has enabled us to treat an

entirely new group of patients that we could not adequately serve with

radiotherapy alone," said Linda F. Winger, vice president of professional

services and research administration at Georgetown University Hospital.

"Accuray is seeing significant demand for the CyberKnife System to

treat extracranial tumors, such as those associated with lung and prostate

cancer," said Euan Thomson, Ph.D., president and CEO of Accuray. "Recently

published reports indicate a potentially significant shortfall in cancer

treatment resources associated with the United States' aging population. As

a pain free, non-invasive, outpatient procedure radiosurgery is ideally

suited to address this growing need. This survey confirms what we have

believed for some time, that the CyberKnife System is the only extracranial

radiosurgery system in widespread use."

Survey Methodology

Dominic & Irvine Research, an independent market research firm,

conducted a survey of more than 1,600 sites by telephone between February

and June of 2006 to determine the nature of the radiation oncology program,

the site's instruments (Linear accelerator, Intensity-Modulated Radiation

Therapy, Image- Guided Radiation Therapy, Stereotactic Radiosurgery, etc.),

and the pattern of usage for the equipment for both intracranial and

extracranial treatments. All-purpose units, as referenced above, include

Varian Medical Systems' Trilogy, Elekta's Synergy® and BrainLAB's

Novalis®. Interviews were conducted with the head or director of

radiation oncology as well as radiation oncologists and physicists at some

sites.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife System represents the next generation of radiosurgery

systems, combining continuous image-guidance technology with a compact

linear accelerator that has the flexibility to move in three dimensions

according to the treatment plan. This combination, which is referred to as

intelligent robotics, extends the benefits of radiosurgery to the treatment

of tumors anywhere in the body. The CyberKnife System autonomously tracks,

detects and corrects for tumor and patient movement in real-time during the

procedure, enabling delivery of precise, high dose radiation typically with

sub- millimeter accuracy.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a

global leader in the field of radiosurgery. Its CyberKnife System is the

world's first and only commercially available intelligent robotic

radiosurgery system designed to treat tumors anywhere in the body,

typically with sub- millimeter accuracy. To date, it is estimated that the

CyberKnife System has been used by physicians to treat more than 20,000

patients worldwide. For more information, please visit

http://www.accuray.com.

Safe Harbor Statement

Except for the historical information contained herein, the matters set

forth in this press release, including statements as to financial guidance,

development, clinical studies, regulatory review and approval, and

commercialization of products, are forward-looking statements within the

meaning of the "safe harbor" provisions of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements speak only as of

the date the statements are made and are based on information available at

the time those statements are made and/or management's good faith belief as

of that time with respect to future events. You should not put undue

reliance on any forward- looking statements. Important factors that could

cause actual performance and results to differ materially from the

forward-looking statements we make include: reimbursement for the

CyberKnife procedure; government approvals of our products; market

acceptance of products; funding requirements; intellectual property

protection for our products; competing products; and other risks detailed

from time to time under the heading "Risk Factors" in Registration

Statement on Form S-1 (Reg. No. 333-138622), and our most recent form 10-Q

filed on March 15, 2007 and may be updated from time to time by our other

filings with the Securities and Exchange Commission. If one or more of

these risks or uncertainties materialize, or if any underlying assumptions

prove incorrect, our actual performance or results may vary materially from

any future performance or results expressed or implied by these forward-

looking statements. We assume no obligation to update forward-looking

statements to reflect actual performance or results, changes in assumptions

or changes in other factors affecting forward-looking information, except

to the extent required by applicable securities laws.

Accuray, the Accuray logo, CyberKnife, Synchrony, Xsight and RoboCouch

are among trademarks or registered trademarks of Accuray Incorporated. All

other marks are property of their respective owners.